Basel, Switzerland (UroToday.com) In the past, androgen deprivation therapy (ADT) was the only available option for metastatic prostate cancer. When looking at data published 15 years ago, approximately 4.4-7% of metastatic patients lived for more than 10 years.1,2 The independent predictors of survival were lower PSA, low volume disease, lack of pain, and lower Gleason score.1 However, in […]
Basel, Switzerland (UroToday.com) Dr. Himisha Beltran gave an overview looking into the future of oligometastatic disease, and where she predicts we will be in two years’ time. The current definition of oligometastatic disease is based on the number of metastases (1-5). Importantly, novel imaging modalities such as PET-PSMA have resulted in defining a worse disease state. […]
Basel, Switzerland (UroToday.com) Dr. Stefano Fanti, a radiologist from Bologna, Italy, gave his point of view on how he sees the future in terms of prostate cancer imaging. He began stating that the use of conventional imaging such as CT and bone scan should be regarded as obsolete starting from now. Novel imaging such as PET […]
Basel, Switzerland (UroToday.com) Dr. Karim Fizazi gave a brief talk on what can be approved in global access to treatment of advanced prostate cancer. His talk began with data on current access to radiotherapy on a worldwide level (Figure 1). This data showed that there is still a long way to go for us to reach […]
Basel, Switzerland (UroToday.com) Dr. Clarke gave a summary talk on the topic of optimization of the treatment of newly diagnosed metastatic prostate cancer. The discussion began on the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000. The scans […]
Basel, Switzerland (UroToday.com) Immunotherapy expert Dr. Charles Drake delivered the immunotherapy for mCRPC at the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The first major successful trial in immunotherapy for prostate cancer was the IMPACT trial in 2010.1 Sipuleucel-T was FDA approved based on results of the phase III IMPACT […]
Basel, Switzerland (UroToday.com) Professor Oliver Sartor from Tulane University discussed the impact and utility of radium-223 at today’s bone and bone metastases session at APCCC 2019. Radium-223 first gained prominence with the reporting of the ALSYMPCA trial in 2013. This phase III trial led to FDA approval of radium-223 in the United States for patients with […]
Basel, Switzerland (UroToday.com) During this discussion, Dr. Gert Attard explained how to maximize therapy of steroids with abiraterone acetate. Abiraterone acetate is currently given for two indications: Newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), with prednisone 5 mg daily. For metastatic castration-resistant prostate cancer (mCRPC) with prednisone 10 mg daily. Abiraterone can cause mineralocorticoid […]
Basel, Switzerland (UroToday.com) Dr. Charles Ryan discussed the management of fatigue and cognitive changes induced by androgen deprivation therapy (ADT). Fatigue in patients treated with ADT is common, occurring in more than 40% of them. The addition of potent androgen receptor (AR) targeting agents may worsen this. Long term ADT may be associated with cognitive changes […]
To determine whether patients can avoid systematic prostate biopsy (PBx) if their Prostate Imaging Reporting and Data System version 2 (PI-RADs v2) score is ≤ 3 and how we clinicians make decisions that can maximize benefit. We reviewed our prospectively maintained database of consecutive men who received transrectal ultrasound-guided 24-core biopsy as well as pre-biopsy multi-parametric magnetic […]
